← All drugs
Drug · FAERS side-effect profile with label screen

Venlafaxine side effects: what 71,196 FDA adverse event reports show

Venlafaxine · 1,219 reaction terms · 312,385 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

71,196 reports · 84% serious · 10,171 with death outcome · 68% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder Venlafaxine extended-release tablets are indicated for the treatment of major depressive disorder (MDD).

FDA label, Indications and Usage

What it is

Venlafaxine extended-release tablets are extended-release tablets for oral administration that contain venlafaxine hydrochloride, USP a structurally novel antidepressant. Venlafaxine hydrochloride, USP is a selective serotonin and norepinephrine reuptake inhibitor (SNRI).

FDA label, Description section

Boxed warning

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 3Labeled (related wording) 6Likely indication confounding 2Lab value / disease marker 4Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,179 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Amyloid arthropathy593,417.5
1,371.7–8,514.8ROR 3,420.3 · calibrated p 1e-17 ✓
246.6 EB05 198.1 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=59 · ♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Malignant mediastinal neoplasm50254.1
173.8–371.4ROR 254.2 · calibrated p 2e-10 ✓
129.2 EB05 101.8 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=50 · ♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Inspiratory capacity decreased101171.1
133.8–218.7ROR 171.3 · calibrated p 3e-9 ✓
105.8 EB05 89.6 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 0% (drug 68%) · 100% clinicianno trial arm names this drug
Neovascularisation5988.1
65.8–117.9ROR 88.2 · calibrated p 5e-7 ✓
66.4 EB05 53.3 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=59 · ♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Amaurosis fugax21875.3
64.9–87.4ROR 75.6 · calibrated p 1e-6 ✓
59.7 EB05 53.3 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=218 · 100% clinicianno trial arm names this drug
Antidepressant drug level above therapeutic4867.2
49.1–91.9ROR 67.2 · calibrated p 3e-6 ✓
53.6 EB05 42.0 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=48 · ♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Temperature regulation disorder31148.8
43.3–55.0ROR 49.0 · calibrated p 2e-5 ✓
41.8 EB05 38.0 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=309 · ♀ 93% (drug 68%)no trial arm names this drug
Postmortem blood drug level increased5148.1
35.8–64.7ROR 48.1 · calibrated p 3e-5 ✓
40.8 EB05 32.3 · IC025 +4.4
3/3 methods agree
Lab value / disease markerserious n=51 · ♀ 0% (drug 68%) · 100% clinicianno trial arm names this drug
Respiratory disorder neonatal20844.2
38.2–51.1ROR 44.3 · calibrated p 3e-5 ✓
38.4 EB05 34.2 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=208 · ♀ 33% (drug 68%)no trial arm names this drug
Physical deconditioning29539.2
34.8–44.3ROR 39.4 · calibrated p 6e-5 ✓
34.6 EB05 31.4 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=295no trial arm names this drug
Serotonin syndrome2,13136.9
35.3–38.5ROR 38.0 · calibrated p 7e-5 ✓
32.8 EB05 31.6 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 23.7 · serious PRR 22.5no trial arm names this drug
Bradycardia neonatal13736.1
30.3–43.2ROR 36.2 · calibrated p 1e-4 ✓
32.1 EB05 27.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=137no trial arm names this drug
Hypotonia neonatal15132.2
27.2–38.1ROR 32.2 · calibrated p 2e-4 ✓
29.0 EB05 25.3 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=151no trial arm names this drug
Agitation neonatal8428.4
22.7–35.5ROR 28.4 · calibrated p 4e-4 ✓
25.8 EB05 21.5 · IC025 +4.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=84no trial arm names this drug
Neonatal asphyxia5625.2
19.2–33.1ROR 25.2 · calibrated p 8e-4 ✓
23.1 EB05 18.4 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=56 · 100% clinicianno trial arm names this drug
Infantile apnoea6425.1
19.4–32.4ROR 25.1 · calibrated p 8e-4 ✓
23.0 EB05 18.7 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=64 · ♀ 0% (drug 68%) · 100% clinicianno trial arm names this drug
Bezoar10724.7
20.3–30.1ROR 24.7 · calibrated p 8e-4 ✓
22.8 EB05 19.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=107 · 100% clinicianno trial arm names this drug
Social anxiety disorder5124.7
18.5–32.8ROR 24.7 · calibrated p 9e-4 ✓
22.6 EB05 17.9 · IC025 +3.8
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious n=50 · ♀ 0% (drug 68%)no trial arm names this drug
Poisoning deliberate70424.0
22.3–26.0ROR 24.3 · calibrated p 8e-4 ✓
22.3 EB05 20.9 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious PRR 15.2 · 100% clinicianno trial arm names this drug
Electric shock sensation20324.0
20.8–27.7ROR 24.1 · calibrated p 9e-4 ✓
22.2 EB05 19.7 · IC025 +4.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=174 · 73% consumerno trial arm names this drug
Foetal death37923.2
20.9–25.7ROR 23.3 · calibrated p 1e-3 ✓
21.5 EB05 19.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=379 · ♀ 100% (drug 68%)no trial arm names this drug
Victim of crime7620.1
16.0–25.4ROR 20.2 · calibrated p 0.002 ✓
18.8 EB05 15.5 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=76 · ♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Drug specific antibody8619.8
15.9–24.6ROR 19.8 · calibrated p 0.002 ✓
18.5 EB05 15.4 · IC025 +3.7
3/3 methods agree
Lab value / disease markerserious n=84 · ♀ 100% (drug 68%) · 100% consumerno trial arm names this drug
Neonatal hypoxia5219.7
14.9–26.1ROR 19.7 · calibrated p 0.003 ✓
18.4 EB05 14.5 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=52 · ♀ 0% (drug 68%) · 100% clinicianno trial arm names this drug
Hyperreflexia20618.4
16.0–21.1ROR 18.4 · calibrated p 0.003 ✓
17.3 EB05 15.4 · IC025 +3.8
3/3 methods agree
Labeled adverse reaction
exact term
serious n=205 · 91% clinicianno trial arm names this drug
Cataplexy8418.3
14.7–22.9ROR 18.4 · calibrated p 0.003 ✓
17.2 EB05 14.3 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=82 · 100% clinicianno trial arm names this drug
Reversible cerebral vasoconstriction syndrome11217.8
14.7–21.5ROR 17.8 · calibrated p 0.004 ✓
16.8 EB05 14.3 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=112 · 100% clinicianno trial arm names this drug
Antipsychotic drug level above therapeutic5017.3
13.0–23.0ROR 17.3 · calibrated p 0.004 ✓
16.3 EB05 12.8 · IC025 +3.4
3/3 methods agree
Lab value / disease markerserious n=49 · ♀ 0% (drug 68%) · 100% clinicianno trial arm names this drug
Emotional poverty9617.0
13.8–20.9ROR 17.0 · calibrated p 0.004 ✓
16.1 EB05 13.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=94 · ♀ 39% (drug 68%) · 100% consumerno trial arm names this drug
Clonus14716.6
14.1–19.6ROR 16.7 · calibrated p 0.005 ✓
15.7 EB05 13.7 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=146 · 100% clinicianno trial arm names this drug
Small for dates baby26616.5
14.6–18.7ROR 16.6 · calibrated p 0.005 ✓
15.7 EB05 14.2 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=266no trial arm names this drug
Sleep-related eating disorder5016.5
12.4–22.0ROR 16.5 · calibrated p 0.005 ✓
15.5 EB05 12.2 · IC025 +3.3
3/3 methods agree
Not in label — unassessed♀ 100% (drug 68%) · 100% clinicianno trial arm names this drug
Food allergy40216.5
14.9–18.2ROR 16.6 · calibrated p 0.005 ✓
15.7 EB05 14.4 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=397 · ♀ 100% (drug 68%)no trial arm names this drug
Large for dates baby4716.4
12.3–22.1ROR 16.4 · calibrated p 0.006 ✓
15.5 EB05 12.0 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=47 · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality7,6049.49.2–9.6signal
Depression3,7293.93.8–4.1signal
Extrapyramidal1,3883.93.7–4.1signal
Seizure2,0513.13.0–3.2signal
Hyponatraemia8203.02.8–3.2signal
Arrhythmia / qt1,8312.82.7–2.9signal
Rhabdomyolysis / myopathy6712.42.3–2.6signal
Dependence / withdrawal2,1892.22.1–2.3signal
Fall / fracture2,5812.01.9–2.1raised
Liver injury1,8621.81.7–1.9raised
Hypoglycaemia5501.71.6–1.8raised
Kidney injury2,5981.71.6–1.7raised
Anaphylaxis / angioedema6371.51.4–1.6raised
Pancreatitis4071.51.4–1.6raised
Gi bleeding8521.41.3–1.5raised
Heart failure7731.31.2–1.4raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Venlafaxine only as a background or rescue medication (NCT01360866, NCT01838681); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)5,7631.3
1.3–1.3ROR 1.3 · calibrated p 0.519
1.3 EB05 1.3 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Nausea4,5621.7
1.7–1.8ROR 1.8 · calibrated p 0.803
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.8no trial arm names this drug
Toxicity to various agents4,4418.0
7.8–8.2ROR 8.4 · calibrated p 0.056
7.8 EB05 7.6 · IC025 +2.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 6.6 · serious PRR 5.5 · 95% clinicianno trial arm names this drug
Off label use (used outside approved label)4,4311.5
1.5–1.5ROR 1.5 · calibrated p 0.668
1.5 EB05 1.5 · IC025 +0.5Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Fatigue (tiredness)4,3581.7
1.6–1.7ROR 1.7 · calibrated p 0.768
1.7 EB05 1.6 · IC025 +0.7Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Headache3,9021.8
1.8–1.9ROR 1.9 · calibrated p 0.882
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 2.1no trial arm names this drug
Completed suicide (death by suicide)3,32612.1
11.7–12.5ROR 12.6 · calibrated p 0.014 ✓
11.6 EB05 11.3 · IC025 +3.5
3/3 methods agree
Outcome field, not a reactionage-adj. PRR 8.8 · serious PRR 7.9 · 97% clinicianno trial arm names this drug
Drug interaction3,2366.1
5.9–6.3ROR 6.4 · calibrated p 0.129
6.0 EB05 5.8 · IC025 +2.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.7 · serious PRR 4.5no trial arm names this drug
Dizziness3,1331.9
1.8–1.9ROR 1.9 · calibrated p 0.887
1.9 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Diarrhoea (diarrhea)2,9011.3
1.3–1.4ROR 1.3 · calibrated p 0.538
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Depression2,6873.5
3.4–3.6ROR 3.6 · calibrated p 0.463
3.5 EB05 3.4 · IC025 +1.7
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.0 · serious PRR 2.8no trial arm names this drug
Pain2,6691.3
1.2–1.3ROR 1.3 · calibrated p 0.501
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.2no trial arm names this drug
Anxiety2,6112.7
2.6–2.8ROR 2.8 · calibrated p 0.704
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 2.5 · serious PRR 2.3no trial arm names this drug
Overdose2,5823.5
3.4–3.7ROR 3.6 · calibrated p 0.452
3.5 EB05 3.4 · IC025 +1.7
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.4 · serious PRR 3.0no trial arm names this drug
Dyspnoea (shortness of breath)2,5361.3
1.3–1.4ROR 1.3 · calibrated p 0.531
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.2no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Venlafaxine (serotonergic antidepressants) ↔ Serotonin syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Venlafaxine?

In FDA FAERS, the most frequently co-reported reaction terms for Venlafaxine are nausea, toxicity to various agents, fatigue, headache, dizziness, diarrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Venlafaxine have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.

Do FAERS signals prove that Venlafaxine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.